PRN PACIFIC RESEARCH NETWORK
3003 Fourth Avenue, San Diego, CA 92103 * (619) 294-4302 Ph. (619) 294-4867 Fax

MARYANN DEAN, M.D.

EDUCATION

2001 – 2002 Psychiatry: University of California, San Diego, California
1998 – 2001 Psychiatry: State University of New York, Buffalo, New York
1994 – 1998 Medical: State University of New York, Buffalo, New York
1991 – 1993 Pre-Medical: State University of New York, Buffalo, New York
1979 – 1981 MFA: West Virginia University, Morgantown, West Virginia
1977 – 1979 BA: West Liberty State College, West Liberty, West Virginia
1970 – 1973 Preparatory: Universidad Nacional Autonoma de Mexico, Mexico City, Mexico

MEDICAL EXPERIENCE

2003 – Present Staff Physician, Pacific Research Network, San Diego, California
2003 – Present Psychiatrist, Private Practice, San Diego, California
2003 – Present Clinical Instructor, Psychiatrist, UCSD Outpatient Services, San Diego, California
2003 – 2008 Psychiatrist, Survivors of Torture International, San Diego, California
2003 – 2006 Psychiatrist, San Diego County Psychiatric Hospital, San Diego, California
2002 – 2003 Psychiatrist, Neighborhood Services and Interfaith Community Services, Escondido, California
1979 Psychiatric Assistant, Northern Panhandle Mental Health Center, Wheeling, West Virginia
1976 Laboratory Assistant, Instituto Mexicano del Seguro Social, Mexico City, Mexico

RESEARCH AND VOLUNTEER ACTIVITIES

1994 Research Assistant, State University of New York, Buffalo, New York
1993 Nursing Assistant, Roberto Clemente Clinic, Buffalo, New York
1992 Assistant, Roswell Park Cancer Institute, Buffalo, New York
1992 Caretaker, Benedict House, Buffalo, New York

CERTIFICATION AND LICENSURE

2003 Board Certification in Psychiatry

LICENSURE: State of California
License Number: A70889
Expiration Date: February 28, 2014

HONORS AND AWARDS

PRITE Award
The Gilbert M. Beck Memorial Prize
Association of Pathology Chairs Award
American Medical Women's Association

PROFESSIONAL ORGANIZATIONS

Member of The National Alpha Omega Alpha Honor Medical Society
Member of the Association of Pathology Chairs Honor Society
Member of the American Psychiatry Association

CLINICAL RESEARCH EXPERIENCE

1. A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of XXXX (150 and 250 mg/day) as Treatment for Adults with Residual Excessive Sleepiness Associated with Obstructive Sleep Apnea/Hypopnea Syndrome (203233)

2. A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of XXXX (150 and 250 mg/day) as Treatment for Adults with Excessive Sleepiness Associated with Narcolepsy (203231)

3. A One Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy and Safety of XXXX in Subjects with Mild Cognitive Impairment (202493)

4. A Randomized, Multicenter, Double-Blind, Placebo-Controlled, 18-Month Study of the Efficacy of XXXX in Patients with Mild-To-Moderate Dementia of the Alzheimer's Type (202793)

5. A Randomized, Double-Blind, Placebo-Controlled Trial of XXXX to Attenuate the Progression of Alzheimer's Disease (202530)

6. A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter, Fixed-Dose, Polysomnographic Study of XXXX in Patients with Primary Insomnia (202700)

7. A Multi-Center, Randomized, Open-Label Study Evaluating the Effects of XXXX, 80 mg b.i.d., vs. XXXX, 5 or 10 mg, on Adrenal Function in Patients with Mild Alzheimer's Disease (202538)

8. An Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of XXXX in the Treatment of Mild Cognitive Impairment (5075)

9. A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of XXXX in Subjects with Mild Cognitive Impairment (MCI) Clinically at Risk for Development of Clinically Probable Alzheimer's Disease (2920)

10. A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of XXXX in Subject with Mild Cognitive Impairment (MCI) Clinically at Risk for Development of Clinically Probable Alzheimer's Disease (2919)

11. A Double-Blind, Placebo-Controlled Dose-Finding Study Evaluating the Safety and Efficacy of XXXX, 80 mg bid, and 20 and 80 mg QD in the Treatment of Mild to Moderate Alzheimer's Disease (4807)

12. A Long Term Safety and Efficacy of Open-Label XXXX, 80 mg b.i.d. in the Treatment of Probable Alzheimer's Disease: A 18-Month Follow-Up After Completion of Study XXXX (202859)

13. A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess the Efficacy and Safety of a Modified Release Formulation of XXXX in Elderly Primary Insomnia Patients with Sleep Maintenance Difficulties (4315)

14. A Phase III, Randomized, Double-Blind, Placebo-Controlled, Outpatient Study To Assess the Long-Term Safety and Efficacy of Two Dose Levels of XXXX in Adult Patients with Primary Insomnia (3934)

15. A Phase III, Randomized, Double-Blind, Placebo-Controlled, Outpatient Study to Assess the Efficacy and Safety of Two Dose Levels of XXXX in Elderly Patients With Primary Insomnia (3931)

16. A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of XXXX 25 mg in Slowing the Progression of Alzheimer's Disease (202531)

17. A Randomized, Double-Blind, Placebo-Controlled, 4-Period-Cross-Over Pilot Study of the Safety and Efficacy of Multiple Doses of XXXX in Subjects with Alzheimer's Disease (202856)

18. An Evaluation of the Long-Term Safety and Efficacy of XXXX in Patients with Moderate to Severe Dementia of the Alzheimer's Type (202891)

19. A 12-Month, Open-Label, Flexible-Dosage Study to Evaluate the Safety of XXXX, at Dosages up to 16 mg/day in Adults with Generalized Anxiety Disorder (202976)

20. Pharmacogenomics Blood Sampling Protocol to Obtain DNA in a Reference Population of Patients Diagnosed with Restless Legs Syndrome (5152)

21. A Long-Term, Open-Label, Flexible-Dose Study of the Efficacy and Safety of XXXX in Patients with Idiopathic Restless Legs Syndrome (4382)

22. An 8-Week, Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Flexible-Dosage Study to Evaluate the Efficacy and Safety of XXXX, at Dosages up to 16 mg/day, in the Treatment of Generalized Anxiety Disorder in Adults (202359)

23. A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of XXXX Monotherapy in Patients with Moderate to Severe Dementia of the Alzheimer's Type (4988)

24. A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of XXXX in Patients with Moderate to Severe Dementia of the Alzheimer's Type (4887)

25. A Long-Term Extension Study Evaluating the Safety and Tolerability of BID and QD Administration of XXXX in Patients with Mild to Moderate Dementia of the Alzheimer's Type (3811x1)

26. A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of XXXX in Patients with Mild to Moderate Dementia of the Alzheimer's Type. IND#: 33,392 (4441)

27. A Phase III, Randomized, Double-Blind, Placebo-Controlled, Outpatient Study to Assess the Long-Term Safety and Efficacy of Two Dose Levels of XXXX in Adult Patients with Primary Insomnia (3934)

28. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Efficacy and Safety of XXXX in Subjects with Mild to Moderate Alzheimer's Disease. (00012)

29. A Study to Define the Non-Restorative Sleep Population. (00010)

30. A Randomized, Double-Blind, Placebo-Controlled Trial of XXXX to Attenuate the Progression of Alzheimer's Disease. (00026)

31. A 6-Month Safety Follow-Up Study of Select Patients Previously Enrolled and Randomized to XXXX in Studies XXXX, XXXX or XXXX. (00028)

32. Evaluation of the Long-Term Efficacy and Safety of XXXX 12.5-mg Compared to Placebo, When Both are Administered Over a Long-Term Period "as needed", in Patients with Chronic Primary Insomnia. (A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter, Phase IIIb Clinical Study). (00007)

33.A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Assess the Efficacy and Safety of XXXX in Patients with Restless Legs Syndrome. (203812PRN)

34.A Phase III Study of the Efficacy and Safety of XXXX in Patients with Mild to Moderate Alzheimer's Disease. (203077PRN)

35.A Double-Blind, Phase II, Safety and Efficacy Evaluation of XXXX in Patients with Mild to Moderate Alzheimer's Disease. (203096PRN)

36.A 12-Month, Open-Label, Flexible-Dosage (100-250 mg/day) Extension Study of the Safety and Efficacy of XXXX in the Treatment of Patients with Excessive Sleepiness Associated with Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder. (203903)

37.A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Immunogenicity Trial of XXXX in Patients with Mild to Moderate Alzheimer's Disease. (00025)

38.A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Once Daily XXXX in Patients with Restless Legs Syndrome. (00036)

39.Phase 3 Multicenter, Randomized, Double Blind, Placebo Controlled Study of the Effect of Daily Treatment with XXXX on Measures of Cognition, Activities of Daily Living and Global Function in Subjects with Mild Dementia of the Alzheimer's Type. (00023)

40.A Phase III, Randomized, Double-Blind, Placebo-Controlled, Polysomnographic Study to Assess the Efficacy and Safety of a Modified Release Formulation of XXXX in Primary Insomnia Patients with Sleep Maintenance Difficulties. (00047)

41.A Double Blind, Placebo Controlled Study of XXXX for the Treatment of Mild-To-Moderate Alzheimer's Disease. (00065)

42.A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of XXXX in Patients with Restless Legs Syndrome. (00056)

43.A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study to Evaluate the Effects of XXXX (2.5, 10 and 30 mg) on Polysomnographic Sleep Recordings, Subjective Sleep Assessment, and Daytime Cognitive Function in Elderly and Nonelderly Subjects with Primary Insomnia. (00088)

44.A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of DHA on Cognitive Functions in the Elderly. (00058)

45.A Randomized, Double-Blind, Placebo Controlled, Cross-Over Study to Evaluate Effects of the XXXX in Patients with Insomnia. (00077)

46.A Randomized, Double-Blind Comparison of 5 mg of XXXX, 15 mg of XXXX, and Placebo in the Treatment of Patients with Primary Insomnia. (00076)

47.A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Evaluate the Efficacy and Safety of XXXX in Migraine Prophylaxis. (00082)

48.A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety and Tolerability of XXXX in Patients with Generalized Anxiety Disorder. (00054)

49.A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Five-Arm Parallel-Group Trial to Investigate the Efficacy and Safety of Four Different Transdermal Doses of XXXX in Subjects with Idiopathic Restless Legs Syndrome. (00046)

50.An Open-Label Extension Trial to Investigate the Safety and Tolerability of Long-Term Treatment with Transdermal XXXX in Subjects with Idiopathic Restless Legs Syndrome. (00093)

51.A Double-Blind, Randomized, Placebo-Controlled, Phase IIa, Multiple Dose, Multicenter Study in Patients with Mild to Moderate Dementia of the Alzheimer's Type to Evaluate the Safety and Tolerability of Two 10-Week Dose Regimens of Orally-Administered XXXX. (00063)

52.The Efficacy of XXXX 3 mg as Adjunctive Therapy in Subjects with Insomnia Related to Generalized Anxiety Disorder (GAD). (00057)

53.A 12 Week, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of XXXX XR (Extended Release) in Patients with Restless Legs Syndrome. (00059)

54.A 52-Week, Open-Label Study to Assess the Long-Term Safety of XXXX Extended Release (XR) in Patients with Restless Legs Syndrome (RLS). (00075)

55.An Open-Label Extension of the Phase III Study XXXX with XXXX in Patients with Alzheimer's Disease. (00107)

56.A 28-Week Open Label Extension Study Evaluating the Safety and Tolerability of XXXX (XXX) in Subjects with Mild Cognitive Impairment. (00105)

57.A Randomized, Double-Blind, Placebo-And Active-Controlled, Multicenter, Proof of Concept Trial of XXXX in Subjects with Non-Restorative Sleep. (00095)

58.A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Demonstrate the Subjective Treatment Effects of XXXX on Sleep Using a Post Sleep Questionnaire-Interactive Voice Response System (PSQ-IVRS) in an “At-Home Setting” in an Adult Population with Chronic Insomnia. (00145)

59.A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of 8 Week Treatment of XXXX 8 mg (QHS) in Sleep Disturbed, Mild to Moderately Severe Alzheimer’s Disease Subjects. (00090)

60.Effect of XXXX in Slowing the Progression of Alzheimer’s Disease. (00134)

61.An 8-Week, Randomized, Double-Blind, Fixed-Dosage, Placebo-Controlled, Parallel-Group, Multicenter Study of the Efficacy, Safety and Tolerability of XXXX 25 mg and 50 mg in the Treatment of Major Depressive Disorder (MDD) Followed by a 52-Week, Open-Label Extension. (00125)

62.Efficacy and Safety of XXXX 5mg/Day on Sleep Maintenance Insomnia: A 6-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. (00103)

63.A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Investigate the Efficacy and Safety of a Single Oral Dose of XXXX (20, 50, and 100 mg) and Matching Placebo in Healthy Male and Female Subjects with Induced Transient Insomnia.

64.An Open-Label, 52-Week Extension Study Assessing XXXX Safety and Efficacy in Patients with Restless Legs Syndrome. (00114)

65.Phase 3 Multinational, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of Daily Treatment with XXXX on Measures of Cognition, Activities of Daily Living and Global Function in Subjects with Mild Dementia of the Alzheimer’s Type. (00128)

66.A 54-Week, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Investigate the Effects of XXXX (Extended Release Tablets) as Adjunctive Therapy to Acetylcholinesterase Inhibitors on Cognition and Overall Clinical Response in APOE €4 Stratified Subjects with Mild to Moderate Alzheimer’s Disease (REFLECT-3), AVA102670. (00123)

67.A Multi-Center, Double-Blind, Parallel Group, Fixed Dose, 4-Arm, Placebo and Paroxetine Controlled 8-Week Efficacy Study of 2 Oral Doses of XXXX (175mg or 350mg, bid) in Adult Outpatients with Major Depressive Disorder. (00022)

68.A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study to Assess the Efficacy, Safety, and Pharmacokinetics of XXXX in Patients with Restless Legs Syndrome. (00141)

69.Open Label Study of the Effect of Daily Treatment with XXXX in Subjects with Dementia of the Alzheimer' Type. (00139)

70.XXXX Dose-Ranging Trial: A Randomized, Double-Blind, Placebo-Controlled, 5-Way Crossover, Multicenter Polysomnography Trial of XXXX in Adults with Primary Insomnia. (00284)

71.A Phase II, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Assessing the Efficacy and Safety of XXXX Tablets Twice Daily in Adults with Mild to Moderate Alzheimer's Disease. (00214)

72.A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Investigate the Efficacy and Safety of XXXX (20mg/Day and 50mg/Day) in the Treatment of Primary Insomnia. (00273)

73.A Randomized, Double-Blind, Active-and Placebo-Controlled, Parallel Group Safety Study Assessing Simulated Driving Performance in XXXX-Treated Patients with Restless Legs Syndrome. (00227)

74.Efficacy and Safety of 2mg/Day XXXX on Sleep Maintenance Insomnia: A 6-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Polysomnographic Study. (00192)

75.A Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study to Assess the Short-Term Effects of XXXX Alone and in Combination with Donepezil in Subjects with Mild Alzheimer's Disease. (00144)

76.A Six-Week, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Efficacy and Safety, Sleep Lab Trial with XXXX in Patients with Chronic Primary Insomnia. (00118)

77.A Phase 2, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Effect on Cognitive Function of XXXX After 12 Weeks of Intranasal Administration in Subjects with Mild Cognitive Impairment. (00163)

78.Fifty-Two Weeks, Open-Label Extension Trial to Evaluate Safety and Efficacy of XXXX in Outpatients with Chronic Primary Insomnia who Completed Clinical Trial Protocol 176001 or 176002. (00217)

79.A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, 10-Week Study Evaluating the Efficacy and Safety of XXXX for the Treatment of Generalized Anxiety Disorder. (00275)

80.A Double-Blind, Randomized, Placebo-Controlled Study Examining, the Safety, Efficacy, and Tolerability of XXXX in Subjects with Major Depressive Disorder (Including Atypical and Melancholic Features). (00230)

81.A Randomized, Double-Blind, Placebo-Controlled, Parallel, Proof of Concept Study to Evaluate the Effectiveness of XXXX to Advance the Timing of Sleep in Individuals with Delayed Sleep Phase Syndrome (DSPS). (00198)

82.A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of XXXX at a Target Dosage of 200mg/Day as Treatment for Adults with Excessive Sleepiness Associated with Obstructive Sleep Apnea/Hypopnea Syndrome With Comorbid Major Depressive Disorder or Dysthymic Disorder. (00323)

83.A Randomized, Long-Term Safety Study of XXXX in Elderly Outpatients with Chronic Primary Insomnia Examining the Effects of 1.5 mg or 3.0 mg of XXXX. (00226)

84.A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of XXXX in Adult Migraineurs for a Single Migraine Followed by Open-Label Extensions to 26/52 Weeks. (00219)

85.A 52-Week Open-Label Extension Study of the Long-Term Safety and Efficacy of XXXX Extended-Release (RSGXR) as Adjunctive Therapy to Acetylcholinesterase Inhibitors in Subjects with Mild-to-Moderate Alzheimer's Disease (AVA102675, REFLECT-4). (00220)

86.XXXX Dose-Ranging Trial: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Outpatient Trial of XXXX in Adults with Non-Restorative Sleep. (00321)

87.A Randomized, Double-Blind, Placebo-Controlled Subjective Study to Assess the Efficacy of XXXX in Patients with Primary Insomnia Characterized by Difficulty Maintaining Sleep. (00324)

88.Effect of y-Secretase Inhibition on the Progression of Alzheimer's Disease: XXXX Versus Placebo. (00294)

89.A Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating the Efficacy and Safety of Eighteen Months of Treatment with XXXX (XXXX) in Participants with Mild-To-Moderate Alzheimer's Disease. (00355)

90.A Phase 2a Multi-Center, Randomized, Double Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of XXXX in Patients with Mild to Moderate Alzheimer's Disease. (00318)

91.A Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Phase 1b Safety Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (XXXX) or Placebo in Patients with Mild to Moderate Probable Alzheimer's Disease. (00343)

92.A 52 Week Open Label Safety Study of XXXX in Subjects with Generalized Anxiety Disorder. (00305)

93.A Polysomnography Study of XXXX (XXXX) Extended Release Tablets Versus Placebo in the Treatment of Restless Legs Syndrome (RLS) and Associated Sleep Disturbance. (00338)

94.Efficacy and Safety of XXXX 5mg/Day in Insomnia Characterized by Sleep Maintenance Difficulties: A 6-Week, Randomized, Double-Blind, Placebo-Controlled, Polysomnography Study. (00350)

95.A Phase 2 Study of XXXX Compared with Placebo for the Treatment of Alcohol Dependence. (00347)

96.A Phase 3 Multicenter, Randomized, Placebo-Controlled, Twelve-Month Safety and Efficacy Study Evaluating XXXX in Patients with Mild-to-Moderate Alzheimer's Disease on Donepezil. (00404)

97.A Double-Blind Placebo-Controlled Preliminary Study of the Efficacy, Safety and Tolerability of XXXX in the Treatment of Alzheimer's Disease. (00382)

98.Randomized, Double-Blind, 12-Month Study of XXXX in Subjects with Restless Legs Syndrome. (00418)

99.A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of XXXX in the Treatment of Patients with Mild to Moderate Alzheimer's Disease. (00341)

100. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of XXXX in the Treatment of Patients with Prodromal Alzheimer's Disease. (00412)

101. A Double-Blind Placebo-Controlled Preliminary Study of the Efficacy, Safety and Tolerability of XXXX in the Treatment of Alzheimer's Disease in Subjects Concurrently Receiving Donepezil (Aricept®). (00403)

102. An Open Label Study of the Safety and Tolerability of XXXX in Subjects with Alzheimer's Disease. (00446)

103. A Randomized, Double-Blind, Placebo-Controlled, Functional Neuroimaging Study of the Effects of XXXX (200 mg/day) Treatment on Prefrontal Cortical Activation in Patients with Residual Excessive Sleepiness Associated with Obstructive Sleep Apnea/Hypopnea Syndrome. (00407)

104. A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of XXXX (50, 150 and 250 mg/day) as Treatment for Patients with Excessive Sleepiness Associated with Mild or Moderate Closed Traumatic Brain Injury. (00397)

105. A Phase 2 Multicenter, Double-Blind, Placebo Controlled, Parallel Group Study of XXXX in Subjects with Mild to Moderate Alzheimer's Disease. (00440)

106. A Randomized, Double-Blind, Placebo-Controlled, 3-Way Crossover, Multicenter Polysomnography Study of XXXX and XXXX in Adults with Restless Legs Syndrome. (00457)

107. A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Long-Term Safety Study of XXXX in Patients with Primary Insomnia. (00448)

108. Open-Label Extension for Alzheimer's Disease Patients who Complete One of Two XXXX Phase 3 Double-Blind Studies (H6L-MC-LFAN or H6L-MC-LFBC). (00516)

109. A 12-Month, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of XXXX (150 and 250 mg/Day) as Treatment for Patients with Excessive Sleepiness Associated with Mild or Moderate Closed Traumatic Brain Injury. (00506)

110. Randomized, Double-Blind, 12-Week Study of XXXX in Subjects with Restless Legs Syndrome. (00515)

111. A Worldwide, Randomized, Double Blind, Placebo-Controlled, Parallel Group Clinical Trial to Evaluate the Safety and Efficacy of XXXX for the Acute Treatment of Migraine in Children and Adolescents. (00502)

112. A Worldwide, Open Label, Clinical Trial to Examine the Long Term Safety and Tolerability of XXXX in Pediatric Migraineurs for the Treatment of Migraine With or Without Aura. (00469)

113. Effect of Passive Immunization on the Progression of Alzheimer's Disease: XXXX (XXXX) Versus Placebo. (00503)

114. A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Study to Evaluate the Safety and Efficacy of XXXX in Patients with Primary Insomnia – Study A. (00514)

115. An Open-Label Extension of the CONCERT Protocol (DIM18) Evaluating XXXX (XXXX) in Patients with Alzheimer's Disease. (00529)

116. Continued Efficacy and Safety Monitoring of XXXX, an Anti-Amyloid β Antibody in Patients with Alzheimer's Disease. (00565)

117. A Multiple Dose Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of XXXX Administered Once Daily to Subjects with an Excessive Daytime Sleepiness Disorder. (00541)

118. A 4-Week, Randomized, Double-Blind, Parallel Group, Placebo Controlled Study to Investigate the Safety and Efficacy of XXXX as Monotherapy in Patients with Treatment-Resistant Major Depression. (00585)

119. A Multicenter, Randomized, Double-Blind, Active-Controlled Study of the Efficacy and Safety of Flexibly-Dosed XXXX in Patients with Treatment Resistant Major Depression. (00571)

120. A Randomized, Double-Blind, Placebo-Controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study to Assess Safety, Tolerability, Immunogenicity, Pharmacodynamic Response, and Pharmacokinetics of Intravenous Infusions of XXXX in Subjects with Mild to Moderate Alzheimer's Disease. (00582)

121. A Phase 2, 24-Month, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Amyloid-Imaging Positron Emission Tomography (PET) and Safety Study of XXXX and XXXX Adjuvant in Subjects with Mild to Moderate Alzheimer's Disease. (00591)

122. A Phase 2, Multicenter, Open-Label Study to Assess the Safety and Tolerability of Oral XXXX as Adjunctive Therapy in Adult Patients with Major Depressive Disorder. (00416)

123. A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of XXXX in Subjects with Spasticity Due to Multiple Sclerosis. (00595)

124. An Open Label, 26-Week Study Assessing XXXX Safety and Efficacy in Subjects with Spasticity Associated With Multiple Sclerosis. (00614)

125. A Phase 1b, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Sequential Dose Study of the Safety and Tolerability of XXXX in Subjects With Alzheimer's Disease on Donepezil. (00618)

126. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of XXXX in Patients With Mild to Moderate Alzheimer's Disease. (00579)

127. A Multicenter, Double-Blind, 58-Week Rollover Study to Assess the Safety and Tolerability of XXXX in Patients With Treatment Resistant Major Depression. (00583)

128. A Study to Evaluate the Effects of XXXX in Patients With Chronic Obstructive Pulmonary Disease. (00619)

129. A Double-Blind, Parallel Group, Randomized, Placebo Controlled Sleep Laboratory Study of Efficacy and Safety of XXXX in Insomnia Patients Aged 18-80. (00635)

130. A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Effectiveness of XXXX (Human), 10% Solution (XXXX, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease (AD). (00626)

131. A Phase IIa Safety and Tolerability Study to Investigate the Effect of Sleep of 3 Doses of XXXX and Placebo in Patients with Mild Alzheimer's Disease and Mild Cognitive Impairment During 4 Weeks of Treatment, Designed as a Randomized, Double-Blind, Multi-Center, Parallel Group, Placebo-Controlled Study. (00658)

132. Effect of XXXX in Obese Subjects with Moderate or Severe Obstructive Sleep Apnoea A 32-Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Centre and Multinational Trial. (00696)

133. A Phase 2, Randomized, Double-Dummy, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of XXXX (XXXX/XXXX) for the Treatment of Symptoms of Agitation in Patients with Alzheimer's Disease. (00697)

134. A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XXXX in Subjects with Prodromal or Mild Alzheimer's Disease. (00700)

135. A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients with Mild to Moderate Alzheimer's Disease. (00729)

136. A Twelve-Week, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Multi-Center Study of the Safety and Efficacy of XXXX in the Treatment of Excessive Daytime Sleepiness in Subjects with Narcolepsy. (00733)

137. Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 18-Month Safety and Efficacy Study of XXXX in Subjects with Mild Alzheimer's Disease. (00722)

138. A 26-Week, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Investigate the Effects of Daily Administration of XXXX in Participants with Mild to Moderate Alzheimer's Disease (AD) with an Optional 26-Week Open-Label Extension. (00731)